Loss of p16 does not protect against premature ovarian insufficiency caused by alkylating agents

Loss of p16 does not protect against premature ovarian insufficiency caused by alkylating agents

Abstract Background Chemical agents such as alkylating agents (AAs) that are commonly used for the treatment of cancer cause great damage to the ovaries, thereby significantly increasing the risk of premature ovarian insufficiency (POI). However, the exact molecules underlying AA-induced POI remain...

Full description

Bibliographic Details
Main Authors: Fei Liu, Qin Wan, Pengfei Liu, Dengshun Miao, Xiuliang Dai, Li Chen
Format: Article
Language:English
Published: BMC 2023-03-01
Series:BMC Pregnancy and Childbirth
Subjects:
Premature ovarian insufficiency
Alkylating agents
p16 deficiency
Folliculogenesis
Online Access:https://doi.org/10.1186/s12884-023-05476-x

Internet

https://doi.org/10.1186/s12884-023-05476-x

Similar Items